Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 5, 2006, Pages 941-957

  Sloof, Gerrit W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CT; EUS; FDG PET; neoadjuvant therapy; oesophageal cancer; therapy response assessment

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NEDAPLATIN; PACLITAXEL; VINCRISTINE;

ACCURACY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; INTERMETHOD COMPARISON; MULTIMODALITY CANCER THERAPY; NON INVASIVE MEASUREMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748706965     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.04.004     Document Type: Article

References (44)

1. Ajani J.A. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the oesophagus. Chest 113 (1998) 112S-119S
2. Sagar P.M., Gauperaa T., Sue-Ling H., et al. An audit of the treatment of cancer of the ooesophagus. Gut 35 (1994) 941-945
3. Hulscher J.B., Tijssen J.G., Obertop H., et al. Transthoracic versus transhiatal resection for carcinoma of the oesophagus: a meta-analysis. Ann Thorac Surg 72 (2001) 306-313
4. Chung S.C., Stuart R.C., and Li A.K. Surgical therapy for squamous-cell carcinoma of the oesophagus. Lancet 343 (1994) 521-524
5. Muller J.M., Erasmi H., Stelzner M., et al. Surgical therapy of ooesophageal carcinoma. Br J Surg 77 (1990) 845-857
6. Daly J.M., Fry W.A., Little A.G., et al. Oesophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190 (2000) 562-572
7. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1733
8. Walker S.J., Allen S.M., Steel A., et al. Assessment of the response to chemotherapy in oesophageal cancer. Eur J Cardiothorac Surg 5 (1991) 519-522
9. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
10. Griffith J.F., Chan A.C., Chow L.T., et al. Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 72 (1999) 678-684
11. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathological assessment of tumour regression after preoperative chemoradiotherapy of oesophageal carcinoma. clinicopathological correlations. Cancer 73 (1994) 2680-2686
12. Jones D.R., Parker Jr. L.A., Detterbeck F.C., et al. Inadequacy of computed tomography in assessing patients with oesophageal carcinoma after induction chemoradiotherapy. Cancer 85 (1999) 1026-1032
13. Rice T.W., Boyce G.A., Sivak M.V., et al. Oesophageal carcinoma: oesophageal ultrasound assessment of preoperative chemotherapy. Ann Thorac Surg 53 (1992) 972-977
14. Hordijk M.L., Kok T.C., Wilson J.H., et al. Assessment of response of oesophageal carcinoma to induction chemotherapy. Endoscopy 25 (1993) 592-596
15. Dittler H.J., Bollschweiler E., and Siewert J.R. What is the value of endosonography in the preoperative staging of oesophageal carcinoma?. Dtsch Med Wochenschr 116 (1991) 561-566
16. Giovannini M., Seitz J.F., Thomas P., et al. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with oesophageal cancer. Endoscopy 29 (1997) 4-9
17. Bowrey D.J., Clark G.W., Roberts S.A., et al. Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the oesophagus. J Gastrointest Surg 3 (1999) 462-467
18. Laterza E., de Manzoni G., Guglielmi A., et al. Endoscopic ultrasonography in the staging of oesophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 67 (1999) 1466-1469
19. Zuccaro Jr. G., Rice T.W., Goldblum J., et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for oesophageal cancer. Am J Gastroenterol 94 (1999) 906-912
20. Beseth B.D., Bedford R., Isacoff W.H., et al. Endoscopic ultrasound does not accurately assess pathological stage of oesophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 66 (2000) 827-831
21. Kroep J.R., Van Groeningen C.J., Cuesta M.A., et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-d-glucose for response monitoring in locally advanced gastrooesophageal cancer: a comparison of different analytical methods. Mol Imaging Biol 5 (2003) 337-346
22. Hirata N., Kawamoto K., Ueyama T., et al. Using endosonography to assess the effects of neoadjuvant therapy in patients with advanced oesophageal cancer. AJR Am J Roentgenol 169 (1997) 485-491
23. Chak A., Canto M.I., Cooper G.S., et al. Endosonographic assessment of multimodality therapy predicts survival of oesophageal carcinoma patients. Cancer 88 (2000) 1788-1795
24. Willis J., Cooper G.S., Isenberg G., et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in oesophageal carcinoma. Gastrointest Endosc 55 (2002) 655-661
25. Isenberg G., Chak A., Canto M.I., et al. Endoscopic ultrasound in restaging of oesophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 48 (1998) 158-163
26. Kostakoglu L., and Goldsmith S.J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 44 (2003) 224-239
27. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
28. Hoekstra C.J., Paglianiti I., Hoekstra O.S., et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27 (2000) 731-743
29. Arslan N., Miller T.R., Dehdashti F., et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-d-glucose with positron emission tomography in patients with oesophageal cancer. Mol Imaging Biol 4 (2002) 301-310
30. Kato H., Kuwano H., Nakajima M., et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with oesophageal cancer. Am J Surg 184 (2002) 279-283
31. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of oesophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21 (2003) 428-432
32. Brucher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of oesophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 (2001) 300-309
33. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
34. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with oesophageal carcinoma. Cancer 101 8 (2004 Oct 15) 1776-1785
35. Cerfolio R.J., Bryant A.S., Ohja B., et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with oesophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129 6 (2005 Jun) 1232-1241
36. Swisher S.G., Maish M., Erasmus J.J., et al. Utility of PET, CT, and EUS to identify pathologic responders in oesophageal cancer. Ann Thorac Surg 78 4 (2004 Oct) 1152-1160 [discussion 1152-1160]
37. Westerterp M., van Westreenen H.L., Reitsma J.B., et al. Oesophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology 236 3 (2005) 841-851
38. Cochrane Methods Working Group on Systematic Review of Screening and Diagnostic Tests. Recommended Methods. Cochrane. 1996 [ref type: electronic citation].
39. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
40. Wieder H.A., Brucher B.L., Zimmermann F., et al. Time course of tumour metabolic activity during chemoradiotherapy of oesophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22 5 (2004) 900-908
41. Roubein L.D., DuBrow R., David C., et al. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the oesophagus and esophagogastric junction. Endoscopy 25 (1993) 587-591
42. Hoekstra C.J., Hoekstra O.S., Stroobants S.G., et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43 (2002) 1304-1309
43. Weber W.A., Ziegler S.I., Thodtmann R., et al. Reproducibility of metabolic measurements in malignant tumours using FDG PET. J Nucl Med 40 (1999) 1771-1777
44. Minn H., Zasadny K.R., Quint L.E., et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 196 (1995) 167-173